+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030: Based on Type of Solution, Type of Therapy and Purpose of Solution

  • ID: 5157421
  • Report
  • July 2020
  • Region: Global
  • 513 Pages
  • Roots Analysis
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 23andMe
  • CapDecisif Management
  • Future.Health
  • LEO Innovation Lab
  • PatientsLikeMe
  • St. Luke's Health System
  • MORE

The “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation))” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of digital therapeutics solutions (either commercialized or under development) in the healthcare industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

  • An overview of the current market landscape of digital therapeutic solutions, including information on status of development, type of solution (combination offering of software application + device or AI or personal coach, and standalone software application), type of therapy (curative and preventive), purpose of solution (medication replacement and medication augmentation), target indication(s), therapeutic area(s), and target population. In addition, it presents details of the companies developing digital therapeutic solution, highlighting year of establishment, company size, type of business model used (B2B and B2C) and location of headquarters.
  • An in depth analysis of the contemporary market trends, presented using four schematic representations, including [A] a bubble analysis comparing the leading players engaged in the development of digital therapeutic solutions based on the parameters, such as product portfolio strength, number of target indication(s) and company size, [B] a grid representation illustrating the distribution of the digital therapeutic solutions based on status of development, type of solution and therapeutic area, [C] an insightful tree map representation of the digital therapeutic solutions, distributed on the basis of therapeutic area and company size, and [D] a world map representation highlighting the regional distribution of developer companies.
  • A detailed product competitiveness analysis of digital therapeutic solutions developed/under development for the most popular therapeutic areas taking into consideration the strength of product portfolio (based on the total number of digital therapeutic solutions being developed in that disease area) and key product specific parameters, such as status of development, type of solution, type of therapy, and purpose of solution.
  • Elaborate profiles of prominent small-sized and mid-sized players that are either engaged in the development or have developed digital therapeutic solutions. Each company profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters and key members of the executive team), details of their respective product portfolio, recent developments and an informed future outlook.
  • A detailed analysis of more than 220 completed, ongoing and planned clinical studies of various digital therapeutic solutions, based on the various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, study design, trial recruitment status and trial focus, highlighting leading sponsors and leading digital therapeutic solutions (in terms of number of trials conducted), type of organization, popular therapeutic areas and regional distribution of trials. In addition, it features an insightful clinical end-points analysis (for trials initiated since 2018 for popular therapeutic areas).
  • An analysis of the investments made in the period between 2009 and 2020 (till June), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field.
  • An analysis of the partnerships that have been inked by stakeholders in this domain, in the period between 2008 and 2020 (till May), covering marketing and distribution agreements, mergers/acquisitions, pilot product offerings, product/technology integration agreements,  product/technology licensing agreements, product development agreements, product evaluation agreements, product training agreements, research and development agreements and product development and commercialization agreements.
  • A detailed analysis of the various business models and go-to-market strategies adopted by companies involved in this space, providing details on various channels adopted/being adopted by stakeholders in the industry to raise awareness and offer access to their proprietary products.
  • A Bowman’s Strategy Clock framework in order to analyze the competitive position of various companies in the marketplace, taking into consideration the prices and different features of their products.
  • An insightful discussion on the impact of COVID-19 pandemic on the overall digital therapeutic solutions market, and the key initiatives undertaken by big pharma players.
  • A review of the key aspects related to the remote digital monitoring and diagnostics solutions, including [A] a brief introduction to remote digital monitoring and diagnostics solutions, highlighting the key benefits and roadblocks [B] an assessment of the market landscape of remote digital monitoring and diagnostics solutions, based on various parameters, such as status of development, type of solution, target disease indication(s) and therapeutic area, along with details on the companies that develop these solutions, highlighting year of establishment, company size and location of headquarters [C] detailed profiles of some of the key players that presently offer digital monitoring/diagnostic solutions for chronic disease management; each profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters, lead investors, key partners and  members of the executive team), details of their product portfolio, recent developments and an informed future outlook, and [D] an insightful analysis on various capital investments that have been made into the digital monitoring/diagnostics domain.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall digital therapeutic solutions industry.
  • An informative analysis of contemporary Google Trends in the time period between 2015 and 2020 (till July) and insights from the recent news articles related digital therapeutic solutions, indicating the increasing popularity of this domain. Furthermore, it highlights the potential future opportunities for players engaged in development of such solutions.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for digital therapeutics developers over the next decade. Based on multiple parameters, likely adoption trends, and expected price variations for these products, we have provided an informed estimate of the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity within digital therapeutics market across [A] type of solution (combination offering of software application + device or AI or personal coach, and standalone software applications), [B] purpose of solution (medication replacement and medication augmentation), [C] type of therapy (curative and preventive), [D] distribution channels (B2C (patients) and B2B (healthcare providers, payers, employers and pharmaceutical companies)), [E] therapeutic areas (cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders, and other disorders), and [F] key geographical regions (North America (the US and Canada), Europe (France, Germany, Italy, Spain and the UK), Asia-Pacific (Australia, China, India, Japan, and South Korea) and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Stephanie Tilenius (Co-Founder and Chief Executive Officer, Vida Health)
  • Adam Kaufman (Chief Executive Officer, Canary Health)
  • Vijay Ravindran (Chief Executive Officer, Floreo)
  • Eran Ofir (Chief Executive Officer, Somatix)
  • Edouard Gasser (Chief Executive Officer, Tilak Healthcare)
  • Palakh R Sarogi (Vice President Marketing, Wellthy Therapeutics), Arani Sarkra (Senior Manager Consumer Marketing, Wellthy Therapeutics) and Yolande D’Mello (Marketing and Public Relations, Wellthy Therapeutics)
  • Amelie Janson (Communication Manager, Voluntis)
  • Anonymous (Founder and Chief Executive Officer, UK based Small-Sized Company)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading developers offering digital therapeutic solutions?
  • What are the most popular therapeutic areas for digital therapeutic solutions?
  • Which companies are actively involved in conducting clinical trials for their solutions?
  • What are the key factors influencing the price of digital therapeutic solutions?
  • What is the trend in capital investments in the digital therapeutics market?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • What type of marketing strategies are being adopted by developers in this domain?
  • What is the impact of COVID-19 outbreak on digital therapeutic solutions market?
  • What are the opportunities for digital therapeutic solutions in emerging markets?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to digital therapeutic solutions market?
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 23andMe
  • CapDecisif Management
  • Future.Health
  • LEO Innovation Lab
  • PatientsLikeMe
  • St. Luke's Health System
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1 Chapter Overview
3.2. Digitization in the Healthcare Sector
3.3. Next-Generation Healthcare Solutions
3.4. Key Concepts Associated with Digital Health Solutions
3.4.1. Cognitive Behavioral Therapy (CBT)
3.4.2. Internet of Things (IoT)
3.4.3. Big Data
3.4.4. Artificial Intelligence (AI)
3.4.5. Gamification
3.5. Overview of Digital Therapeutics
3.5.1. Key Strategic Initiatives
3.5.1.1. Digital Therapeutics Alliance (DTA)
3.5.1.2. Personal Connected Health (PCH) Alliance
3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)
3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)
3.5.1.5. National Health Service (NHS) Guidelines
3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics
3.5.2. Product Development and Commercialization Path for Digital Therapeutics
3.5.2.1. Discovery and Preclinical Phase
3.5.2.2. Clinical Trials and Validation
3.5.2.3. Involving Insurance Providers / Payers
3.5.2.4. Distribution and Marketing

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall Market Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Solution
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Purpose of Solution
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Target Population
4.3. Digital Therapeutics: Additional Information
4.3.1. Analysis by Prescription Requirement
4.3.2. Analysis by Duration of Course
4.3.3. Analysis by Cost of Solution
4.4. Digital Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Type of Business Model
4.4.4 Analysis by Location of Headquarters
4.5. Leading Developers: Analysis by Number of Digital Therapeutics Solutions
4.6. Leading Developers: 4D Bubble Analysis based on Portfolio Strength, Target Indication and Company Size
4.7. Grid Representation: Analysis by Status of Development, Type of Solution and Therapeutic Area
4.8. Tree Map Representation: Analysis by Therapeutic Area and Company Size
4.9. World Map Representation: Analysis of Regional Activity
4.10. Digital Therapeutics: Information on Additional Companies

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions / Key Parameters
5.4. Key Therapeutic Areas
5.4.1. Cardiovascular Disorders
5.4.1.1. Product Competitiveness Analysis
5.4.2. Mental Health Problems
5.4.2.1. Product Competitiveness Analysis
5.4.3. Metabolic Disorders
5.4.3.1. Product Competitiveness Analysis
5.4.4. Neurological Disorders
5.4.4.1. Product Competitiveness Analysis
5.4.5. Substance Use Disorders
5.4.5.1. Product Competitiveness Analysis
5.4.6. Other Therapeutic Areas
5.4.6.1. Product Competitiveness Analysis

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Akili Interactive
6.2.1 Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Big Health
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. dreem
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5 Kaia Health
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Mindmaze
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Omada Health
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Pear Therapeutics
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3 Recent Developments and Future Outlook
6.9. Vida Health
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Voluntis
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. WellDoc
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook
6.12. Wellthy Therapeutics
6.12.1. Company Overview
6.12.2. Product Portfolio
6.12.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Digital Therapeutics: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Number of Patients Enrolled and Trial Registration Year
7.3.4. Analysis by Study Design
7.3.5. Analysis by Trial Recruitment Status
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Leading Industry Players: Analysis by Number of Registered Trials
7.3.8 Leading Digital Therapeutic Solutions: Analysis by Number of Registered Trials
7.3.9. Analysis by Trial Focus
7.3.10. Analysis by Therapeutic Area
7.3.11. Geographical Analysis by Number of Clinical Trials
7.3.12. Geographical Analysis by Trial Recruitment Status
7.3.13. Geographical Analysis by Enrolled Patient Population
7.4. Clinical End-Points Analysis

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. Digital Therapeutics: Funding and Investment Analysis
8.3.1. Analysis by Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Type of Therapy
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Geography
8.3.7. Most Active Players: Analysis by Number of Funding Instances
8.3.8. Most Active Players: Analysis by Amount of Funding
8.3.9. Most Active Investors: Analysis by Number of Instances
8.4 Concluding Remarks

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Digital Therapeutics: Recent Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.2.1. Analysis by Type of Partnership and Year of Partnership
9.3.2.2. Analysis by Type of Partnership and Company Size
9.3.3. Analysis by Type of Partner
9.3.3.1. Analysis by Type of Partner and Year of Partnership
9.3.3.2. Analysis by Type of Partner and Type of Partnership
9.3.4. Analysis by Type of Therapy
9.3.4.1. Analysis by Type of Therapy and Type of Partnership
9.3.4.2. Analysis by Type of Therapy and Type of Partner
9.3.5. Analysis by Therapeutic Area
9.3.5.1. Analysis by Therapeutic Area and Year of Partnership
9.3.5.2 Analysis by Therapeutic Area and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Regional Analysis
9.3.8. Intercontinental and Intracontinental Agreements

10. GO-TO-MARKET STRATEGY
10.1. Chapter Overview
10.2. Marketing Strategies Adopted by Digital Therapeutic Developers
10.2.1. Participation in Global Events
10.2.2. Marketing on Social Media Platforms
10.2.3. Marketing on Online / Print Media Platforms
10.2.4. Undertaking Various Promotional Activities through Official Websites
10.2.5. Adoption of Different Business Models and Pricing Strategies
10.2.5.1. B2C Business Model
10.2.5.2. B2B Business Model
10.2.5.2. B2B2C Business Model
10.2.6. Undertaking Various Promotional Activities through Product Add-ons
10.3. Concluding Remarks

11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS
11.1. Chapter Overview
11.2. Bowman Strategy Clock
11.2.1. Two Dimensions of Bowman Strategy Clock
11.2.2. Eight Positions on Bowman Strategic Clock
11.3 Framework
11.3.1. Methodology
11.3.2. Theoretical Framework and Price Evaluation Hypothesis
11.3.3. Results and Interpretation
11.3.3.1. Product Price Evaluation Matrix: Based on Status of Development
11.3.3.2. Product Price Evaluation Matrix: Based on Type of Solution
11.3.3.3. Product Price Evaluation Matrix: Based on Purpose of Solution
11.3.3.4. Product Price Evaluation Matrix: Based on Type of Therapy
11.3.3.5. Product Price Evaluation Matrix: Based on Therapeutic Area
11.3.3.6. Product Price Evaluation Matrix: Based on Prescription Requirement
11.3.3.7. Product Price Evaluation Matrix: Based on Duration of Course
11.3.3.8. Product Price Evaluation Matrix: Based on Distribution Channel
11.4. Concluding Remarks

12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market, 2020-2030
12.4. Global Digital Therapeutics Market: Distribution by Type of Solution
12.4.1. Digital Therapeutics Market for Standalone Software Applications, 2020-2030
12.4.2. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2020-2030
12.4.3. Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2020-2030
12.4.4. Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2020-2030
12.4.5. Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2020-2030
12.4.6. Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2020-2030
12.4.7. Digital Therapeutics Market for Other Types of Solutions, 2020-2030
12.5. Global Digital Therapeutics Market: Distribution by Purpose of Solution
12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, 2020-2030
12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, 2020-2030
12.6. Global Digital Therapeutics Market: Distribution by Type of Therapy
12.6.1 Digital Therapeutics Market for Curative Therapy, 2020-2030
12.6.2. Digital Therapeutics Market for Preventive Therapy, 2020-2030
12.7. Global Digital Therapeutics Market: Distribution by Business Model
12.7.1. Digital Therapeutics Market for B2C Model (Patients and Caregivers), 2020-2030
12.7.2. Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2020-2030
12.8. Global Digital Therapeutics Market: Distribution by Therapeutic Area
12.8.1. Digital Therapeutics Market for Cardiovascular Disorders, 2020-2030
12.8.2. Digital Therapeutics Market for Chronic Pain, 2020-2030
12.8.3. Digital Therapeutics Market for Mental Health Problems, 2020-2030
12.8.4. Digital Therapeutics Market for Metabolic Disorders, 2020-2030
12.8.5. Digital Therapeutics Market for Neurological Disorders, 2020-2030
12.8.6. Digital Therapeutics Market for Respiratory Disorders, 2020-2030
12.8.7. Digital Therapeutics Market for Sleep Disorders, 2020-2030
12.8.8. Digital Therapeutics Market for Substance Use Disorders, 2020-2030
12.8.9. Digital Therapeutics Market for Other Disorders, 2020-2030
12.9. Global Digital Therapeutics Market: Distribution by Geography
12.9.1 Digital Therapeutics Market in North America, 2020-2030
12.9.1.1 Digital Therapeutics Market in the US, 2020-2030
12.9.1.2 Digital Therapeutics Market in Canada, 2020-2030
12.9.2 Digital Therapeutics Market in Europe, 2020-2030
12.9.2.1. Digital Therapeutics Market in France, 2020-2030
12.9.2.2. Digital Therapeutics Market in Germany, 2020-2030
12.9.2.3. Digital Therapeutics Market in Italy, 2020-2030
12.9.2.4. Digital Therapeutics Market in Spain, 2020-2030
12.9.2.5. Digital Therapeutics Market in the UK, 2020-2030
12.9.2.6. Digital Therapeutics Market in Rest of Europe, 2020-2030
12.9.3. Digital Therapeutics Market in Asia-Pacific, 2020-2030
12.9.3.1. Digital Therapeutics Market in Australia, 2020-2030
12.9.3.2. Digital Therapeutics Market in China, 2020-2030
12.9.3.3. Digital Therapeutics Market in India, 2020-2030
12.9.3.4. Digital Therapeutics Market in Japan, 2020-2030
12.9.3.5. Digital Therapeutics Market in South Korea, 2020-2030
12.9.3.6. Digital Therapeutics Market in Rest of Asia-Pacific, 2020-2030
12.9.4. Digital Therapeutics Market in Rest of the World, 2020-2030

13. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK
13.1. Chapter Overview
13.2. Impact of Coronavirus Pandemic on Digital Therapeutics
13.2.1. Impact on Future Market Opportunity for Digital Therapeutic Solutions Market
13.3. Recuperative Strategies for Developer Businesses
13.3.1. Strategies for Implementation in the Short / Mid Term
13.3.2. Strategies for Implementation in the Long Term

14. REMOTE DIGITAL MONITORING / DIAGNOSTIC SOLUTIONS
14.1. Chapter Overview
14.2. An Introduction to Remote Digital Monitoring / Diagnostic Solutions
14.3. Remote Digital Monitoring / Diagnostic Solutions: Overall Market Landscape
14.3.1. Analysis by Status of Development
14.3.2. Analysis by Type of Solution
14.3.3. Analysis by Target Disease Indication(s)
14.3.4. Analysis by Therapeutic Area
14.3.5. Grid Representation: Analysis by Status of Development, Type of Solution, and Therapeutic Area
14.4. Remote Digital Monitoring / Diagnostic Solutions: List of Developers
14.4.1. Analysis by Year of Establishment
14.4.2. Analysis by Company Size
14.4.3. Analysis by Location of Headquarters
14.5. Remote Digital Monitoring / Diagnostic Solutions: Company Profiles
14.5.1. AliveCor
14.5.1.1. Company Snapshot
14.5.1.2. Product Portfolio
14.5.1.3. Recent Developments and Future Outlook
14.5.2. Bioserenity
14.5.2.1. Company Snapshot
14.5.2.2. Product Portfolio
14.5.2.3. Recent Developments and Future Outlook
14.5.3. Cue
14.5.3.1. Company Snapshot
14.5.2.2. Product Portfolio
14.5.2.3. Recent Developments and Future Outlook
14.5.4. Kinsa
14.5.4.1. Company Snapshot
14.5.4.2. Product Portfolio
14.5.4.3. Recent Developments and Future Outlook
14.6. Remote Digital Monitoring / Diagnostic Solutions: Funding and Investment Analysis
14.6.1. Types of Funding
14.6.2. Remote Digital Monitoring / Diagnostic Solutions: List of Funding and Investments
14.6.2.1. Analysis by Number of Funding Instances
14.6.2.2. Analysis by Amount Invested
14.6.2.3. Analysis by Type of Funding
14.6.2.4. Most Active Players: Analysis by Number of Funding Instances
14.6.2.5. Most Active Players: Analysis by Amount Invested
14.6.2.6. Most Active Investors: Analysis by Number of Funding Instances
14.7. Concluding Remarks

15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Comparison of SWOT Factors
15.2.1. Strengths
15.2.2. Weaknesses
15.2.3. Opportunities
15.2.4. Threats

16. DIGITAL SOLUTIONS: RECENT TRENDS AND FUTURE OPPORTUNITIES
16.1. Chapter Overview
16.2. Prevalent Trends Related to Digital Therapeutics
16.2.1. Emerging Focus Areas
16.2.2. Key Historical Trends
16.2.3. Geographical Distribution of Activity
16.3. Trends Shaping the Future of Digital Therapeutics
16.3.1. Digital Solutions Closing the Digital Gap
16.3.2. Increasing Focus on Patient Centric Models  
16.3.3. Applicability across a Variety of Disease Indications
16.3.4. Increasing Emphasis on Real-World Evidence in Research and Development
16.3.5. Advances in IT and Computing Power to Foster Future Innovation
16.4. Improving the Future Health: Opportunities Beyond Digital Therapeutics

17. EXECUTIVE INSIGHTS
17.1. Chapter Overview
17.2. Vida Health
17.2.1. Company Snapshot
17.2.2. Interview Transcript: Stephanie Tilenius, Co-Founder and Chief Executive Officer
17.3. Canary Health
17.3.1. Company Snapshot
17.3.2. Interview Transcript: Adam Kaufman, Chief Executive Officer
17.4. Floreo
17.4.1. Company Snapshot
17.4.2. Interview Transcript: Vijay Ravidran, Chief Executive Officer
17.5. Somatix
17.5.1. Company Snapshot
17.5.2. Interview Transcript: Eran Ofir, Chief Executive Officer
17.6. Tilak Healthcare
17.6.1. Company Snapshot
17.6.2. Interview Transcript: Edouard Gasser, Chief Executive Officer
17.7. Wellthy Therapeutics
17.7.1. Company Snapshot
17.7.2. Interview Transcript: Palakh R Saraogi, Vice President Marketing, Arani Sarkra, Senior Manager Consumer Marketing, and Yolande D’Mello, Marketing and Public Relations
17.8. Voluntis
17.8.1. Company Snapshot
17.8.2. Interview Transcript: Amelie Janson, Communications Manager
17.9. Anonymous
17.9.1. Interview Transcript: Anonymous, Founder and Chief Executive Officer

18. APPENDIX 1: TABULATED DATA

Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • 23andMe
  • CapDecisif Management
  • Future.Health
  • LEO Innovation Lab
  • PatientsLikeMe
  • St. Luke's Health System
  • MORE

Overview

Chronic disorders, such as arthritis, diabetes, cancer, obesity and heart disease, are considered to be the leading causes of death and disability across the world. Specifically, the global prevalence of diabetes is estimated to be more than 300 million adults by 2025. According to the WHO, more than 450 million people are presently suffering from some form of mental health disorder (such as anxiety and depression), and/or neurological disorder. The rise in number of patients suffering from such clinical conditions continues to impose a significant burden on the global healthcare system. Specifically, in the US, it was estimated that approximately 90% of the country’s annual healthcare expenditure was on patients suffering from various chronic and mental health conditions.

Digital health solutions represent a relatively new concept, which was introduced into mainstream healthcare a few years ago. Such solutions are presently believed to possess the potential to reshape the practice of healthcare. Typically, digital therapeutics are available in the form of various types of gamified solutions, and/or standalone software applications, sometimes featuring active, personalized coaching support, or artificial intelligence (AI) enabled support. The ongoing COVID-19 pandemic and the mandatory enforcement of social distancing measures have created a significant demand for remote healthcare solutions. In fact, China introduced a range of digital solutions throughout different stages of the outbreak, immediately after the coronavirus spread.  Recently, the USFDA also issued certain guidelines on usability of digital therapeutics (specifically for psychiatric conditions), allowing patients to receive treatment at home, minimizing visits to clinics/hospitals, thereby, reducing risk of exposure to the novel coronavirus. Moreover, several companies are actively striving to create and launch solutions that not only allow patients to diagnose and confirm disease symptoms, and consult with doctors/physicians remotely, but also offer therapeutic aid. Although the focus of such companies is presently on diabetes, mental health disorders and musculoskeletal injuries, experts believe that digital therapeutics may eventually replace/augment traditional treatment measures, with clinically validated software. ,    

It is worth noting that there are several successful start-ups focused on designing and development of digital therapeutics; in fact, most such companies are backed by noteworthy investors. A number of digital health solutions are already in the market, and several other innovative solutions are under development. It is worth highlighting that for certain digital health solutions, reimbursement options are also available. In addition, several companies are focused on expanding their offerings to support the management of the COVID-19 pandemic. As the demand for digital solutions gradually rises, pioneers in this domain are likely to benefit the most from increased product sales.

Note: Product cover images may vary from those shown
4 of 5
  • 23andMe
  • 2breathe Technologies
  • 2Morrow
  • 3.life
  • 30Ventures
  • 3M Ventures
  • 500 Startups
  • 5AM Ventures
  • 7wire Ventures
  • 98point6
  • A Better Weigh
  • AARDEX
  • Abbott
  • AbbVie
  • Aberdare Ventures
  • ACC
  • Accel Diagnostics
  • Accolade
  • Adage Capital Management
  • Adams Street Partners
  • Advanced Circulatory Systems
  • Advantage Consumer Healthcare
  • AET Fund
  • Aetna
  • Afterbook
  • Agro Group International Holdings
  • AIMMED
  • Airbus
  • Akili Interactive
  • Al-Ahli Hospital
  • Alex therapeutics
  • Alexandria Venture Investments
  • Alfvén & Didrikson
  • AliveCor
  • All4Life
  • Allen & Company
  • Alsace Business Angels
  • AltaMed
  • Amalgam
  • Amar Seva Sangam
  • AME Cloud Partners
  • American Association of Diabetes Educators
  • American Diabetes Association
  • American Society of Mechanical Engineers
  • American Telemedicine Association
  • Amgen Venture
  • Amiko Digital Health
  • Ampersand Health
  • Ana Health
  • Andreessen Horowitz
  • Anorak Ventures
  • Anthem
  • Aperture Venture Partners
  • Aplastic Anemia & MDS International Foundation
  • Apple
  • AppliedVR
  • Apricity Health
  • Arab Angel
  • Arboretum Ventures
  • Areta Health
  • Argon Global Healthcare
  • Arthritis New Zealand
  • Arthro Therapeutics
  • Asabys Partners
  • Ascensia Diabetes Care
  • Ascension Brighton Center for Recovery
  • Ascension Brighton Center for Recovery
  • ascure STEPS
  • Aspect Ventures
  • Association of Municipalities of Ontario
  • Astellas Pharma
  • Asthma and Allergy Foundation of America
  • AstraZeneca
  • AT&T
  • Athelas
  • ATX Therapeutics
  • Australasian College of Behavioural Optometrists (ACBO)
  • Autism Learning Partners
  • Axess4you
  • BackerNation
  • Baillie Gifford
  • Balderton Capital
  • Banco Sabadell
  • Baseline Ventures
  • Bayer
  • Bayer G4A
  • Beats Medical
  • Beaumont Hospital
  • BeCareLink
  • Beehive Holdings
  • BEENEXT
  • BehaVr
  • BeHealth Solutions
  • BeneTalk
  • Beneufit
  • Berger & Moore Advisors
  • Berklee's Institute for Creative Entrepreneurship
  • Bessemer Venture Partners
  • Beta Wave Consulting
  • Betr Health
  • Better Therapeutics
  • Betterise
  • Betterise Health Tech
  • Beyond Next Ventures
  • Big Health
  • Bigpoint
  • Bimark
  • BIOCORP
  • Bioepic
  • Biomark
  • BioSerenity
  • BioTrak Therapeutics
  • Biotricity
  • BioVentures Investors
  • Birla Institute of Technology and Science
  • BJC Healthcare
  • Blackbird Ventures
  • bLife
  • Bloom Burton
  • Blue Cross Blue Shield Venture Partners
  • Blue Mesa Health
  • Blue Note therapeutics
  • Blue Shield of California
  • Blue Spark Technologies
  • Blueprint Health
  • BOC Healthcare
  • Bodyport
  • Bold Health
  • Bonit Capital
  • Bose Ventures
  • Boston Medical Center
  • Boston University
  • Boulder Care
  • Bpifrance Large Venture
  • Brain Power
  • BrainCheck
  • Brainmarc
  • Breastlink
  • Breed Reply
  • BreezoMeter
  • Breyer Capital
  • Bridge Builders Collaborative
  • Brilliant & Company
  • Bristol-Myers Squibb
  • Broadway Video Ventures
  • Brooklands Capital Strategies
  • BSdp
  • Burrill & Company
  • Burst IQ
  • Burston
  • Business Development Bank of Canada
  • Business Health Care Group
  • Caffeinated Capital
  • Caixa Capital Micro II
  • Caixa Capital TIC II
  • Cambia Health Solutions
  • Canaan Partners
  • Canary Health
  • Cancer Research Collaboration (CRC)
  • Canepa Advanced Healthcare Fund
  • Canvas Ventures
  • CapDecisif Management
  • Capricorn ICT Arkiv
  • CareFirst
  • Carrot Health
  • Cascade Centers
  • Caspar
  • Castlight Health
  • Catasys
  • Cavendish Global
  • CAVU Venture Partners
  • Cedars-Sinai Medical Center
  • Celebrate the Children
  • Celgene
  • CellScope
  • Center for Autism Research (CAR)
  • Center for Managing Chronic Disease, University of Michigan
  • Center for the Advancement of Science in Space
  • Central Illinois Angels
  • Centria Healthcare
  • Centria Healthcare Autism Services
  • CF Hero
  • CheckUp & Choices
  • Chester County Intermediate Unit
  • Chibagin Capital
  • Chicago Ventures
  • Children’s Community Health Plan
  • Children’s Hospital of Philadelphia Center for Autism Research
  • Children's Hospital of Philadelphia
  • Cigna
  • Cigna Ventures
  • Cipla
  • CIS Agriferts
  • City Light Capital
  • Civilization Ventures
  • Claritas MindSciences
  • CleanSlate Research and Education Foundation
  • Click Therapeutics
  • Clinakos
  • CLSA
  • CM-CIC Innovation
  • Cognivive
  • Cognoa
  • Cohan Veteran’s Bioscience
  • COLOPL VR Fund
  • Columbia University Medical Center
  • Columbia University Medical Center
  • Community College System of New Hampshire
  • Community Health Network of Connecticut
  • Company K Partners
  • Compassware
  • Competitive Health
  • Comprehensive Pain Specialists
  • Connecticut Innovations
  • CoreHealth Technologies
  • Correlation Ventures
  • COWEN
  • CPS Capital Group
  • CRCM Ventures
  • Creandum
  • Crista Galli Ventures
  • Crohn's & Colitis Foundation
  • Crossroads Treatment Centers
  • CUCO Health
  • Cue
  • CureApp
  • Currae Healthtech
  • CVS Health
  • Cyberdine
  • Cyrcadia Asia
  • Cyrcadia Health
  • dacadoo
  • Dacuda
  • Dai-ichi Life
  • DAK Gesundheit
  • DancingMind
  • DaneVest Tech Fund
  • Dartmouth College
  • Data Collective
  • David Benshoof Klein
  • daVinci Digital Therapeutics
  • DCM
  • Deerfield Management
  • Delivering Scientific Innovation for Autism
  • Dendera Ventures
  • Dentsu Ventures
  • Department of Veteran Affairs
  • Dexcom
  • DG Ventures
  • Didriksons
  • Digbi Health
  • Digital Health
  • Digitalis
  • Digithera
  • DigiTx Partners
  • dLife
  • DN Capital
  • Doctor on Demand
  • Doctoriya
  • Doha Tech Angels
  • Draper Fisher Jurvetson
  • DrChrono
  • Dreamit Ventures
  • dreem
  • Droobi Health
  • dRx Capital
  • Dthera Sciences
  • dThx – Digital Therapeutics
  • DTM
  • Duke University School of Medicine
  • Early Signal
  • Echo Health Ventures
  • eClinicalHealth
  • Eco-Fusion
  • EDBI
  • Ehave
  • Electric Lime
  • Electronics and Telecommunication Research Institute (ETRI)
  • Elevation Capital
  • Eli Lilly
  • Ellume
  • Embr Labs
  • Emory University
  • Empatica
  • Empire Capital Partners
  • Endeavor Catalyst
  • Endotronix
  • Essex Woodlands
  • European Commission
  • European Pain Federation
  • European School on Interdisciplinary Tinnitus Research
  • Eva Ventures
  • EVERSANA
  • evivecare
  • Evolve Foundation
  • Excel Venture Management
  • Exosystems
  • Facebook
  • Fearless Ventures
  • Felicis Ventures
  • Ferrer
  • Fifty Years
  • Finnish Student Health System (FSHS)
  • FireStarter Fund
  • FirstMark Capital
  • FitBit
  • FITJOY
  • Flare Capital Partners
  • Flatiron Investors
  • Floodgate
  • Floreo
  • Florida Hospital
  • Flying Health
  • Focus DataScience
  • Force Over Mass Capital
  • Ford Motor Company
  • Forward Partners
  • Founder Collective
  • Founders Factory
  • Founders Fund
  • Founders Health
  • Fred Hutchinson Cancer Research Center
  • Freelands Ventures
  • Freestyle Capital
  • Frist Center for Autism and Innovation
  • Fruit Street
  • Frumtak Ventures
  • Fuerst Technology Innovations
  • Future.Health
  • FuturePeds
  • FWD Takaful
  • GAIA
  • Gait Up
  • GC VR Tracker Fund
  • GE Ventures
  • Gelt Venture Capital
  • Genentech, a subsidiary of Roche
  • General Catalyst
  • Gennev
  • Genoa Telepsychiatry
  • George Washington University School of Medicine
  • Georgian Partners
  • Giant Leap
  • Ginger
  • GlaxoSmithKline
  • Global Founders Capital
  • GlobalYeast
  • Go Clinic
  • Go Digital KSA
  • Golden Seeds
  • Google
  • Grammelot
  • GrayMatters Health
  • Great Heights Family Medicine
  • Greg Badros
  • Greycroft
  • GreyGreen
  • GrowX Venture Management
  • GSR Ventures
  • GuideWell Mutual Holding Corporation
  • Haas F1 Team
  • Habitual
  • Hanmi IT
  • Happify Health
  • Harbor Pacific Capital
  • Harrison Metal
  • Healios
  • Health Allliance Plan
  • Health Care Originals
  • Health Catalyst
  • Health Mates
  • Health Transformation Alliance
  • HealthPartners
  • HealthReveal
  • HealthSlate
  • HealthTap
  • HealthX Ventures
  • Healthy Trucking Association of America
  • Heart Foundation
  • Heartcore Capital
  • Helios Orion
  • HelloFresh
  • Highmark Health
  • Highmark Intera   ctive
  • High-Tech Gründerfonds
  • Higi
  • Hikma Ventures
  • Hinduja Group
  • Hintsa Performance
  • Hospices Civils de Lyon
  • Hospital Universitario Reina Sofía
  • Hudson River Capital Partners
  • Human API
  • Humana
  • Hustle Fund
  • Hyde Park Angels
  • Hygieia
  • I Mercury Capital
  • I2A Fund
  • IBB Beteiligungsgesellschaft
  • iBionext
  • IBM
  • Idinvest Partners
  • IEEE
  • iFeel Labs
  • IIFL Select Equity Fund
  • i-Mercury Capital
  • Immortalana
  • IMPACT Accelerator
  • Impact First Investments
  • IMS Health
  • Incos Invest
  • Index Ventures
  • Initialized Capital
  • inMotion VR
  • Innogest Capital
  • Innovate Health Tech NYC
  • Innovate UK
  • Innovation Capital
  • Innovation Works
  • Innovationsstarter Fonds Hamburg
  • Institut de la Vision
  • Insulet
  • INTAGE Holdings
  • Intel Capital
  • Intermountain Healthcare
  • Intermountain Ventures
  • International Finance Corporation (IFC)
  • Intervest
  • Invest Detroit Ventures
  • Invitalia Ventures
  • Ironwood Pharmaceuticals
  • iSeed Ventures
  • iSono Health
  • Israel Innovation Authority
  • Itochu
  • ITOCHU Technology Ventures
  • Iwagin Jigyo Souzou Capital
  • JamJar Investments
  • Janssen Research & Development
  • JAZZ Venture Partners
  • Jett Capital Advisors
  • JOGO Health
  • John Hopki    ns University
  • Johns Hopkins School of Hygiene and Public Health
  • Johnson & Johnson
  • Joint Academy
  • Joslin Diabetes Center
  • Joyable
  • Joyance Partners
  • Jumpstart Ventures
  • Juvenile Diabetes Research Foundation T1D fund
  • K Cube Ventures
  • K2 Investment Partners
  • KAC Health
  • Kaia Health
  • Kaiser Permanente Ventures
  • Kakao Ventures
  • Kapor Capital
  • Karuna Labs
  • Keio Innovation Initiative
  • Kelvi
  • Kentucky Science and Technology
  • Kentucky Science Center
  • Khosla Ventures
  • Kiio
  • King River Capital
  • King's College London
  • Kinnevik
  • Kinsa
  • Kleiner Perkins
  • Kleiner Perkins Caufield & Byers
  • KORE Digital Health Therapeutics
  • Korea Advanced Institute of Science and Technology
  • Koshidaka
  • KTB Network
  • Kurbo Health
  • Kurma Diagnostics
  • Kwit    
  • Kyma Medical Technologies
  • KYT-Know Your Treatment
  • Laidir Foundation
  • Landmark Benefits
  • Lark Health
  • Launchpad Digital Health
  • Launchpad Venture Group
  • LB Investment
  • LBO France
  • Learn Capital
  • Leman Micro Devices
  • LEO Innovation Lab
  • Lief Therapeutics
  • Life Sciences Discovery Fund
  • LifeForce Capital
  • Lifeforce Ventures
  • Lifeline Ventures
  • LifeScan
  • LifeScan
  • Lifespot Health
  • Lifestyle & Wellness Medical Center
  • LifeWave Biomedical
  • Lightspeed Venture Partners
  • Limbix
  • LindaCare
  • LionBirds
  • Liquid 2 Ventures
  • Lirio
  • LiveBetter
  • Livongo Health
  • Louisiana Department of Health
  • Luminopia
  • Lumira Capital
  • LumiraDx
  • Lumosity
  • Lund University
  • Lux Capital
  • Luz Saude
  • Lyfebulb
  • M Ventures
  • M12
  • M3 Ventures
  • m8 Capital
  • Macadamian
  • Magellan Health
  • Mahana Therapeutics
  • MAIF Avenir
  • Mangrove Capital Partners
  • Manipal Education & Medical Group
  • Manipal Education and Medical Group
  • MAP Health Management
  • Map My Health
  • Maryland Technology Development Corporation (TEDCO)
  • MassChallenge
  • Maven Clinic
  • Maverick Ventures
  • Max Healthcare
  • Mayfield Fund
  • McLaren Racing
  • MDLIVE
  • MediPeace Vietnam
  • Medomnia
  • MedRhythms
  • MedTech Innovator
  • Medtronic
  • Meliora Technology
  • Melon Health
  • Memorado
  • Merck
  • Merck Global Health Innovation Fund
  • Merck Ventures
  • Mersey Care NHS Foundation Trust
  • Meru Health
  • metaMe
  • Mevoked
  • mHealth Technologies
  • Mid-Atlantic Telehealth Resource Center
  • MindBeacon Group
  • MindMaze
  • MindSciences
  • Mindset Health
  • MINES & Associates
  • Ministry of Health, Manatu Hauora
  • MIO Global
  • MIT Hacking Medicine
  • MIT Venture Mentoring Service
  • Mitsubishi UFJ Capital
  • Mizuho Capital
  • MJog
  • Mobio Technologies
  • Monarch Medical Technologies
  • Montage Ventures
  • Mori Trust
  • Morningside Group
  • Morningside Ventures
  • Murray-Bertron
  • My mhealth
  • MyLife ID
  • mySugr
  • Naluri
  • Naluri Hidup
  • Nanobiosym Diagnostics
  • Nanon
  • NantHealth
  • National Aeronautics and Space Administration
  • National Cancer Institute
  • National Cancer Research Institute
  • National Institute of Biomedical Imaging and Bioengineering
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of Health
  • National Institute of Mental Health and Neuro Sciences
  • National Institute on Drug Abuse (NIDA)
  • National Institutes of Health
  • National Institutes on Aging
  • National Multiple Sclerosis Society
  • National Rheumatoid Arthritis Society
  • National Science Foundation
  • Navitus Health Solutions
  • Nemaura Medical
  • neuraltrain
  • NeuroCure
  • NeuroMetrix
  • Neurotrack
  • New Enterprise Associates
  • New Mexico Retiree Health Care Authority (NMRHCA)
  • New World Ventures
  • Newsenselab
  • Newtopia
  • Nexeon MedSystems
  • NextGen Venture Partners
  • NGP Capital
  • NHL Alumni Association
  • NightWare
  • Nike
  • Nimble Ventures
  • Nimbus Synergies
  • Noaber Foundation
  • nOCD.
  • NODEHealth
  • Nokia Growth Partners
  • Noom
  • North Texas Angel Network
  • North York General Hospital
  • Northwell Ventures
  • Norwest Venture Partners
  • Norwich Ventures
  • Novant Health
  • Novartis
  • Novator Partners
  • Novo Nordisk
  • NOVOSI
  • Nueon
  • Nunaps
  • Nutrimental Healthcare
  • NuvoAir
  • Obvious Ventures
  • Ocean Azul Partners
  • Octopus Ventures
  • Oklahoma Life Science Fund
  • Omada Health
  • Omidyar Technology Ventures
  • OMRON Global
  • Oncology Care Home Health
  • Oncology Care Home Health Specialists
  • Onduo
  • Ontario Telemedicine (OTN)
  • Ontario Telemedicine Network
  • Open Medicine Institute
  • Optum Ventures
  • Oracle
  • Orexo
  • Orla DTx
  • Oscilloscape
  • OSF Ventures
  • Otsuka America
  • Otsuka Pharmaceutical
  • Oxford Academic Health Science Network
  • Oxford Finance
  • Oxford University
  • Pallasite Ventures
  • Palo Alto Health Sciences
  • Palo Alto Medical Foundation
  • Parasail Health
  • PatientsLikeMe
  • Payor Logic
  • PayPal
  • PBJ Capital
  • Pear Therapeutics
  • Pegasus Tech Ventures
  • Personal Health Solutions
  • Pfizer
  • Phenomenelle Angels
  • Philips
  • Pico Interactive
  • Pinetree capital
  • Pinterest
  • Pioneer Fund
  • Pittsburgh Life Sciences Greenhouse
  • Pixie Scientific
  • Pixvana
  • Plan International
  • Playground Global
  • Plug and Play Tech Center
  • PMV
  • Podimetrics
  • Pond Capital
  • POPS! Diabetes Care
  • Premera Blue Cross
  • Presence Capital
  • Prestige Health Choice
  • Prism Healthcare
  • Pritzker Group Venture Capital
  • Prognos Health
  • Progyny
  • Promus Ventures
  • Propeller Health
  • Prority Health
  • Proteus Digital Health
  • Prototron
  • Provenance Venture Forum
  • Providence Health & Services
  • Providence Ventures
  • Psious
  • Purdue University
  • PureTech Health
  • Qardio
  • Qatar Development Bank
  • Qatar Science & Technology Park
  • Qiming Venture Partners
  • Qualcomm Ventures
  • Quinze-Vingts National Ophthalmology Hospital
  • Quotas Beteiligungs
  • R7 Partners
  • Rally Health
  • RB Investments
  • ReachLink
  • Reaktor Ventures
  • Real Appeal
  • Recruit Strategic Partners
  • Red One Medical
  • RedBrick Health
  • Redmile Group
  • Redox
  • Reflectance Medical
  • RegenConBio
  • Renalis
  • ResApp Health
  • Research Foundation for The State University of New York
  • Research Institute of Sant Pau
  • Research Society for The Study of Diabetes in India (RSSDI)
  • Restore Health
  • Rethink Impact
  • Retrofit
  • Revon Systems
  • Rewire
  • RhythmiaBreath
  • Ridgefield Public Schools
  • RMDY Health
  • Roche
  • Rock Health
  • Romulus Capital
  • Rothenberg Ventures
  • RRE Ventures
  • S.R. One
  • Saama Capital India Advisors
  • Safar Partners
  • Safeguard Scientifics
  • Sagamok Anishnawbek
  • Saison Ventures
  • Salesforce
  • Salumedia
  • Samsung
  • Samsung Electronics
  • Samsung Health
  • Samsung Venture Investment
  • Sandoz
  • Sanitas
  • Sanner
  • Sanner Ventures
  • Sano Intelligence
  • Sanofi
  • Sapphire Ventures
  • Sarjan Health
  • SBRI Healthcare
  • Schoolhouse Partners
  • Schooner Consulting
  • SciFi VC
  • Scrum Ventures
  • Seattle Children’s Research Institute
  • Second Nature
  • Self Care Catalysts
  • selfit health
  • Selfit Medical
  • Selfridges
  • SENACTI
  • Sennheiser
  • Seoul National University Bundang Hospital
  • Sequoia Capital
  • Servier
  • ShapeUp
  • Sharecare
  • Shenzhen JRW Technology
  • Sherpa Capital
  • Shionogi
  • Shire
  • Shire Pharmaceuticals
  • Sidekick Health
  • Signia Venture Partners
  • Silicon Valley Bank
  • Silicon Valley TMS
  • SilverCloud Heath
  • Sino Portfolio International
  • Siren Care
  • Slow Ventures
  • Social Capital
  • Social Starts
  • Solera Health
  • Somatix
  • SOMPO Digital Lab
  • Sompo Japan Nipponkoa
  • Sonormed
  • Sony Innovation Fund
  • Sophia Bendz
  • SOS Ventures
  • Sosna + Co
  • Sound Life Sciences
  • Sozo Ventures
  • Sparknet (India) Marketing
  • Sparo
  • Spectrum Equity
  • Spire
  • Spotify
  • Spring Ridge Ventures
  • Sprint Accelerator
  • St. Joseph's Care Group
  • St. Jude Medical
  • St. Luke's Health System
  • St. Michael's Hospital
  • Stanford University School of Medicine
  • Stanley Park Ventures
  • Startmate
  • Startup Funding Club
  • StartUp Health
  • Startupbootcamp Digital Health Berlin
  • Stateline Angels
  • Steelcase
  • Storm Ventures
  • Stress Point Health
  • SUSMED
  • Sutter Health
  • SV Life Sciences
  • Sweet Capital
  • Swift Medical
  • Swing Therapeutics
  • Swiss Re
  • SyncMed
  • Synovation Medical Group
  • TALi Digital
  • Talkspace
  • Technology Development Fund (TDF)
  • Techstars
  • Teijin
  • Teladoc Health
  • Telcare
  • Telefonica
  • Temasek
  • Temasek Holdings
  • The Aplastic Anemia & MDS International Foundation
  • The Canadian Tire Wickenheiser World Female Hockey Festival
  • The Cancer Research Collaboration
  • The Carlyle Group
  • The Chernin Group
  • The Learning Corp
  • The Research Foundation for The State University of New York
  • The Robotics Hub
  • The Sync Project
  • The Valley Fund
  • The Venture Reality Fund
  • The Vertical Group
  • TheraTec
  • Think Patients
  • Think.Health
  • Thrive Capital
  • Tiatros
  • TiE Boston Angels
  • Tilak Healthcare
  • Tipp ecanoe County Government
  • Tokyo Century
  • Tower Capital Partners
  • Train 24/8
  • TransLink Capital
  • TreeHouse Health
  • Trend Forward Capital
  • TrialSpark
  • TriplePoint Capital
  • TriplePoint Ventures
  • Triumf Health
  • True Ventures
  • True Wealth Ventures
  • TT Capital Partners
  • Tuesday Capital
  • Turnaround Health
  • Twine Health
  • Twitter
  • U.S. Department of Veteran Affairs
  • U.S. Venture Partners
  • UCB
  • Ultra Testing
  • Uncork Capital
  • Unique Nutrition Solutions
  • United Healthcare
  • University Medical Center Goettingen
  • University of Bern
  • University of California
  • University of California Davis
  • University of Hamburg
  • University of London
  • University of Lubeck
  • University of Maryland
  • University of Massachusetts Medical School
  • University of Michigan
  • University of Missouri
  • University of Nebraska
  • University of Nebraska Medical Center
  • University of New York
  • University of North Carolina
  • University of Oxford
  • University of Pennsylvania
  • University of Rochester
  • University of Texas at Dallas
  • University of Texas Southwestern Medical School
  • University of Washington
  • UpLift Health
  • UPMC Enterprises
  • VA Palo Alto Health Care System (VAPAHCS)
  • Valerio Rosso
  • Valeritas Holdings
  • Validic
  • Vanguard Medical Group
  • Venrock
  • Venture Kick
  • Verily Life Sciences
  • Vertical Group
  • Vesalius Biocapital
  • Vheda Health
  • Vida Health
  • Vigo
  • Village Global
  • Vimeo
  • Virgin Atlantic
  • Virgin Pulse
  • Virta Health
  • VirtualScopics
  • Virtue Health
  • Vitadio
  • Vital Art and Science
  • Vital Labs
  • Vitality Group
  • Vivid Vision
  • VNR Vignana Jyothi Institute of Engineering and Technology
  • Volar Health
  • Voluntis
  • VSP Vision Care
  • Wake Forest University
  • Wakestream Ventures
  • Wanxiang America
  • Washington State Department of Health
  • Washington University School of Medicine
  • Wayra
  • WEA Trust
  • Welkin Health
  • Wellbe
  • WellDoc
  • WellDyneRx
  • Wellington Management
  • Wellthy Therapeutics
  • Welltoc
  • Welltrinsic Sleep Network
  • West Coast Primary Health Organization
  • Wicks Digital Health
  • Wildflower Brands
  • William Morris Endeavor
  • William Osler Health System
  • Windham Venture Partners
  • Wisconsin Investment Partners
  • Withings
  • Wonderfull Wellness
  • Wonju Severance Christian Hospital
  • Workday Ventures
  • Workit Health
  • World Health Organization
  • WP Global Partners
  • WTF Health
  • XING
  • Xtreme Labs
  • Y Combinator
  • Yale University
  • Z3VR
  • Zaffre Investments
  • Zillion
  • ZOLL Medical
  • Zyus
Note: Product cover images may vary from those shown
5 of 5

 

 

Loading
LOADING...

Adroll
adroll